Interleukin‐33 antibody failed to demonstrate benefit in a phase II, double‐blind, randomized, placebo‐controlled study in adult patients with moderate‐to‐severe atopic dermatitis
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21631
Abstract: individuals. While this finding was not statistically significant, it may be of clinical significance. A delay in time to definitive surgery may contribute to the disproportionate morbidity observed in this population. Our data demonstrate that… read more here.
Keywords: likely undergo; hispanic patients; high risk; interleukin antibody ... See more keywords